New Delhi: National Pharmaceutical Pricing Authority (NPPA) has brought 80 plus medicines under Price Regulation. NPPA has fixed the price of 81 medicines including off-patent anti-diabetic drugs allowing due benefits of patent expiry to the patients.
NPPA has fixed the Retail Price of Insulin Human Injection, 200IU/ml and 70 per cent Isophane Insulin Human Suspension 30 per cent Insulin Human Injection 200IU/ml for M/s Wockhardt Ltd at 106.65 rupees per ml each excluding GST and Prasugrel Hydrochloride 10 mg as film-coated Aspirin 75 mg as enteric-coated Capsule’for M/s Torrent Pharmaceuticals Ltd. at 20.16 rupees per Capsule excluding GST with effect from 17th March 2021.
Both the medicines were being sold at MRP of 132.50 rupees per ml and at 27.26 rupees per capsule. With this price regulation, NPPA has re-assured availability of medicines at fair prices to public at large.
NPPA had granted price exemption for above-mentioned formulations to the companies under Para 32 of the Drug Prices Control Order (DPCO), 2013 for a period of five years due to new drug delivery system developed through indigenous Research and Development. Price regulation was not applicable during the exemption period. NPPA in its meeting on 10th of this month decided to regulate the price of these formulations as per provisions of DPCO, 2013 as the exemption period has been over.
This has resulted in reduction of the prices of Insulin Human Injection, 200IU/ml and 70 per cent Isophane Insulin Human Suspension 30 per cent Insulin Human Injection 200IU/ml’, causing sizeable reduction over the existing prices. Now, these medicines have become more affordable to the public.
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th of this month to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
In addition, NPPA fixed ceiling price of 2 scheduled formulation namely Povidone Iodine 7.5 per cent Scrub an anti-infective formulation and Levo-Thyroxine 37.5 mg tablet used for treatment of Thyroid related diseases, causing considerable reduction to their present prices.
Revision in existing ceiling prices of scheduled formulations based on the Wholesale Price Index (WPI) was also approved by the Authority. The revised prices will be effective from next month.